[HTML][HTML] Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance
Exosomes are natural nanovesicles excreted by many cells for intercellular communication
and for transfer of materials including proteins, nucleic acids and even synthetic therapeutic …
and for transfer of materials including proteins, nucleic acids and even synthetic therapeutic …
Tumor microenvironment in glioblastoma: Current and emerging concepts
P Sharma, A Aaroe, J Liang… - Neuro-Oncology …, 2023 - academic.oup.com
Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex
system, which in addition to cancer cells, consists of various resident brain and immune cells …
system, which in addition to cancer cells, consists of various resident brain and immune cells …
Nanomedicine for brain cancer
CNS tumors remain among the deadliest forms of cancer, resisting conventional and new
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
treatment approaches, with mortality rates staying practically unchanged over the past 30 …
[HTML][HTML] Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics
Glioblastoma multiforme is the most aggressive malignant tumor of the central nervous
system. Due to the absence of effective pharmacological and surgical treatments, the …
system. Due to the absence of effective pharmacological and surgical treatments, the …
Mouse models of glioblastoma for the evaluation of novel therapeutic strategies
Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15
months despite an aggressive standard of care that includes surgery, chemotherapy, and …
months despite an aggressive standard of care that includes surgery, chemotherapy, and …
Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma
Purpose: Glioblastoma is the most frequent and lethal primary brain tumor. Development of
novel therapies relies on the availability of relevant preclinical models. We have established …
novel therapies relies on the availability of relevant preclinical models. We have established …
Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment
Glioblastoma (GBM) is one of the most aggressive and deadliest central nervous system
tumors, and the current standard treatment is surgery followed by radiotherapy with …
tumors, and the current standard treatment is surgery followed by radiotherapy with …
Dissecting and rebuilding the glioblastoma microenvironment with engineered materials
Glioblastoma (GBM) is the most aggressive and common form of primary brain cancer.
Several decades of research have provided great insight into GBM progression; however …
Several decades of research have provided great insight into GBM progression; however …
Rationally designed drug delivery systems for the local treatment of resected glioblastoma
Glioblastoma (GBM) is a particularly aggressive brain cancer associated with high
recurrence and poor prognosis. The standard of care, surgical resection followed by …
recurrence and poor prognosis. The standard of care, surgical resection followed by …